Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 10/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604525 | 0.84 | GHSR (0.50) | GHSR | |
| SCHEMBL3615808 | 0.81 | HDAC8 (0.49) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL17726457 | 0.79 | GHSR (0.56) | GHSR | |
| SCHEMBL3599583 | 0.78 | GHSR (0.49) | GHSR | |
| SCHEMBL3616932 | 0.77 | GHSR (0.48) | GHSR | |
| SCHEMBL3607676 | 0.76 | GHSR (0.49) | GHSR | |
| SCHEMBL17726266 | 0.76 | GHSR (0.53) | GHSR | |
| SCHEMBL3993278 | 0.75 | ESR2 (0.44) | GHSR | |
| SCHEMBL17726458 | 0.75 | GHSR (0.55) | GHSR | |
| SCHEMBL19642977 | 0.74 | HDAC1 (0.45) | GHSRTTRNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | GHSR 4556/4885CA12 2370/4885CA4 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.